Abstract library

6 results for "Wirtz".
#803 Analysis of Somatostatin-Receptor 2A (SSTR2A) Immunohistochemistry, RT-qPCR and In-Vivo- PET/CT Data in Patients with Pancreatic Neuroendocrine Neoplasm
Introduction: Ga-68 somatostatin receptor (SSTR) PET/CT is one of the most sensitive imaging methods for pancreatic neuroendocrine tumors.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Daniel Kaemmerer
#833 The Chemokine Receptor CXCR4 – Differential Expression in Bronchopulmonary Neuroendocrine Neoplasms
Introduction: The CXCR4 is a plasma membrane chemokine receptor, which is involved in organogenesis, hematopoiesis and inflammation. Additionally, an over-expression is described for many neoplastic tissues. Here, an involvement in tumor progression, metastasis, adaptation to hypoxia and in stem cell survival is postulated.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Christiane Anne Reimann
#877 Immunohistochemical and qRT-PCR-Based Evaluation of Somatostatin Receptor 1 to 5 Expression in 92 Patients with Bronchopulmonary Neuroendocrine Neoplasms
Introduction: Little is known about the somatostatin receptor (SSTR) status in bronchopulmonary neuroendocrine neoplasms (BP-NEN), comprising typical carcinoids (TC), atypical carcinoids (AC), small cell lung cancer (SCLC) and large cell neuroendocrine lung carcinomas (LCNEC).
Conference: 11th Annual ENETS Conference (2014)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Elisa Specht
#879 The Assessment of Proliferation in BP-NEN Entities Based on the Three Proliferation Markers Ki-67, TOP2A and RacGAP1
Introduction: The extent of cell proliferation as an important component of carcinogenesis can be detected in tumor tissues by means of various factors.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Elisa Specht
#1162 Comparative Marker Assessment in Small Cell Lung Cancer with Good and Poor Prognosis
Introduction: Small cell lung cancers (SCLC) are highly aggressive and poorly differentiated neuroendocrine neoplasms which comprise ̴̴̴15 % of all lung malignancies.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Lydia Schmidt
#1524 Is mTOR Pathway Activity a Good Predictor for Everolimus Therapy? A Pilot Study to Build Up a Phase II Trial in Pancreatic Neuroendocrine Neoplasias (pNENs)
Introduction: Everolimus (EVE) is an approved treatment for progressive well-differentiated pNENs and usually induces stable disease. Until now, there is no reliable biomarker for the response to EVE.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: PD Dr. Patricia Grabowski